Associated Papers
Clinical characteristics of female Fabry disease patients with hypertrophic cardiomyopathy with mid-ventricular obstruction.
Inagaki N et al.
Molecular Genetics and Metabolism Reports, 2025
Oxidative stress biomarkers in Fabry disease: is there a room for them?
Simoncini C et al.
Journal of Neurology, 2020
Clinical and genetic backgrounds of hypertrophic cardiomyopathy with mid-ventricular obstruction.
Inagaki N et al.
Journal of Human Genetics, 2018
Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
Duro G et al.
International Journal of Molecular Sciences, 2018
The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.
Benjamin ER et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017
27657681 (PubMed )
Supplement: gim2016122x1.zip › Supplemental_Appendix_2_12152015.xlsx › Non-Classic
Novel alpha-galactosidase A mutation in a female with recurrent strokes.
Tuttolomondo A et al.
Clinical Biochemistry, 2012
Select a paper to view details